SciSparc and Clearmind Medicine Collaboration Results in Publication of Application for Innovative Ketamine-Based Combination
Friday, August 30, 2024
SciSparc Ltd., a clinical-stage specialty pharmaceutical company focused on developing therapies for central nervous system disorders and rare diseases, announced today that its ongoing collaboration with Clearmind Medicine Inc., a biotechnology company dedicated to creating novel psychedelic-derived therapeutics for under-treated mental health issues, has resulted in the publication of a patent application under the international Patent Cooperation Treaty. This application covers innovative combinations of ketamine and N-acylethanolamines.
As part of their collaboration, SciSparc and Clearmind are researching combination treatments that include SciSparc’s Palmitoylethanolamide (PEA) and Clearmind’s novel psychedelic molecule, MEAI, aimed at treating addictions, promoting weight loss, and addressing mental health disorders. Additionally, the partnership is exploring new treatment possibilities involving psychedelic molecules and PEA. To date, the collaboration has led to the filing of thirteen patents with the U.S. Patent and Trademark Office, as well as several other global patent offices.
The U.S. Food & Drug Administration (the “FDA”) gave its approval in 2019 for a ketamine derivative as a nasal spray medication, intended for two specific uses in adult patients: treating depression that has not responded to other treatments and alleviating depressive symptoms in those with major depressive disorder who are having suicidal thoughts or exhibiting suicidal behavior.
The approved treatment comes with strict usage guidelines. It must be administered only at certified medical facilities and used alongside an antidepressant medication. After receiving a dose, patients are required to remain at the facility for a two-hour observation period. This allows healthcare providers to monitor for any potentially serious side effects that may occur.
“SciSparc has always been focused on the development of unique and proprietary combinations with PEA, which our research shows can dramatically reduce the number of doses of various active ingredients while maintaining effectiveness and minimizing adverse effects. Ketamine was approved by the FDA for use under close supervision due to its accompanying side effects. Our innovative approach aims to deliver therapeutic benefits to a diverse group of patients with various conditions, while minimizing unwanted adverse effects. We believe this approach could improve treatment outcomes across a broad spectrum of medical needs,” said Oz Adler, Chief Executive Officer of SciSparc.
Source: scisparc.com
